The potential of GM-CSF to improve resistance against infections in organ transplantation

Trends in Pharmacological Sciences

Volumn 25, Issue 5, 2004, Pages 254-258

  Xu, Jian ^a   Lucas, Rudolf ^a   Wendel, Albrecht ^a  

^a UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; DEXAMETHASONE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; TACROLIMUS;

CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; GRAFT REJECTION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RESISTANCE; LIVER GRAFT; LIVER TRANSPLANTATION; MEDICAL EXAMINATION; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SKIN ALLOGRAFT;

EID: 2142659293     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2004.03.007     Document Type: Article

References (40)

1. Bush W.W. Overview of transplantation immunology and the pharmacotherapy of adult solid organ transplant recipients: focus on immunosuppression. AACN Clin. Issues. 10:1999;253-269
2. Stark K., et al. Immunisations in solid-organ transplant recipients. Lancet. 359:2002;957-965
3. Patel R., Paya C.V. Infections in solid-organ transplant recipients. Clin. Microbiol. Rev. 10:1997;86-124
4. Fishman J.A., Rubin R.H. Infection in organ-transplant recipients. New Engl. J. Med. 338:1998;1741-1751
5. Almawi W.Y., Melemedjian O.K. Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor. J. Leukoc. Biol. 71:2002;9-15
6. Yu X., et al. Advances in transplantation tolerance. Lancet. 357:2001;1959-1963
7. Toungouz M., et al. Tolerance induction in clinical transplantation: the pending questions. Transplantation. 75:2003;58S-60S
8. Salama A.D., et al. Challenges to achieving clinical transplantation tolerance. J. Clin. Invest. 108:2001;943-948
9. Reding R. Steroid withdrawal in liver transplantation: benefits, risks, and unanswered questions. Transplantation. 70:2000;405-410
10. Knechtle S.J. Clinical trials: where are we now? Immunol. Rev. 196:2003;237-246
11. LaRocco M.T., Burgert S.J. Infection in the bone marrow transplant recipient and role of the microbiology laboratory in clinical transplantation. Clin. Microbiol. Rev. 10:1997;277-297
12. Singh N. Infections in solid organ transplant recipients. Curr. Opin. Infect. Dis. 13:2000;343-347
13. Jochimsen F., et al. Late-onset cytomegalovirus reactivation in critically ill renal transplant patients. Transplantation. 76:2003;430-432
14. Tolkoff-Rubin N.E., Rubin H. New strategies for the control of viral infection in organ transplantation. Clin. Transplant. 9:1995;255-259
15. Bueno J., et al. Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients. Paediatr. Drugs. 4:2002;279-290
16. Vilchez R.A., et al. The pathogenesis and management of influenza virus infection in organ transplant recipients. Transpl. Infect. Dis. 4:2002;177-182
17. Armitage J.O. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 92:1998;4491-4508
18. Tiegs G., et al. Potentiation by granulocyte macrophage colony-stimulating factor of lipopolysaccharide toxicity in mice. J. Clin. Invest. 93:1994;2616-2622
19. Bundschuh D.S., et al. Granulocyte-macrophage colony-stimulating factor and IFN-gamma restore the systemic TNF-alpha response to endotoxin in lipopolysaccharide-desensitized mice. J. Immunol. 158:1997;2862-2871
20. Randow F., et al. In vitro prevention and reversal of lipopolysaccharide desensitization by IFN-gamma, IL-12, and granulocyte-macrophage colony-stimulating factor. J. Immunol. 158:1997;2911-2918
21. Williams M.A., et al. Granulocyte-macrophage colony-stimulating factor induces activation and restores respiratory burst activity in monocytes from septic patients. J. Infect. Dis. 177:1998;107-115
22. Williams M.A., et al. Monocyte anergy in septic shock is associated with a predilection to apoptosis and is reversed by granulocyte-macrophage colony-stimulating factor ex vivo. J. Infect. Dis. 178:1998;1421-1433
23. Jaeger K., et al. GM-CSF increases in vitro the respiratory burst of human neutrophils after liver transplantation. Intensive Care Med. 25:1999;612-615
24. Flohe S., et al. Influence of granulocyte-macrophage colony-stimulating factor (GM-CSF) on whole blood endotoxin responsiveness following trauma, cardiopulmonary bypass, and severe sepsis. Shock. 12:1999;17-24
25. Hashmi A., et al. Use of rHu GM-CSF in renal-transplant patients developing leukopenia. Transplant. Proc. 29:1997;3053
26. Trindade E., et al. Use of granulocyte macrophage colony stimulating factor in children after orthotopic liver transplantation. J. Hepatol. 28:1998;1054-1057
27. Ippoliti G., et al. Sequential use of G-CSF and GM-CSF after heart-lung transplantation. J. Heart Lung Transplant. 16:1997;473-475
28. Ferguson T.A., Green D.R. T cells are just dying to accept grafts. Nat. Med. 5:1999;1231-1232
29. Xu J., et al. GM-CSF restores innate, but not adaptive, immune responses in glucocorticoid-immunosuppressed human blood in vitro. J. Immunol. 171:2003;938-947
30. Pfeffer K., et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell. 73:1993;457-467
31. Rothe J., et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature. 364:1993;798-802
32. Heystek H.C., et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) has opposing effects on the capacity of monocytes versus monocyte-derived dendritic cells to stimulate the antigen-specific proliferation of a human T cell clone. Clin. Exp. Immunol. 120:2000;440-447
33. Zhai Y., et al. Modulation of alloimmunity to major histocompatibility complex class I by cotransfer of cytokine genes in vivo. Transpl. Immunol. 6:1998;169-175
34. Devereaux S., et al. GM-CSF accelerates neutrophil recovery after autologous bone marrow transplantation for Hodgkin's's disease. Bone Marrow Transplant. 4:1989;49-54
35. Klingemann H.G., et al. Recombinant GM-CSF in patients with poor graft function after bone marrow transplantation. Clin. Invest. Med. 13:1990;77-81
36. Greenberg P., et al. GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 18:1996;1057-1064
37. Sureda A., et al. GM-CSF administration enhances granulocytic recovery in purged autologous bone marrow transplantation for acute lymphoblastic leukemia. Prog. Clin. Biol. Res. 377:1992;315-320
38. Ho A.D., et al. Utilization of recombinant human GM-CSF to enhance peripheral progenitor cell yield for autologous transplantation. Bone Marrow Transplant. 7:1991;13-17
39. Advani R., et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma. Ann. Intern. Med. 116:1992;183-189
40. Avigan D., et al. Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation. Clin. Cancer Res. 5:1999;2735-2741